Journal article
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate
Cancer chemotherapy and pharmacology, Vol.76(3), pp.439-445
09/01/2015
DOI: 10.1007/s00280-015-2803-y
PMID: 26082421
Abstract
Abiraterone acetate is a novel irreversible inhibitor of CYP17 that was recently approved for men with post-chemotherapy or chemo-naive castration-resistant prostate cancer. Unfortunately, this agent is not curative, and patients often ultimately develop resistance. However, men who progress after treatment with this new hormonal agent may be considered for another line of chemotherapy-based treatment. In 2004, docetaxel (D) and prednisone were found to improve survival compared with older regimens. More recently, cabazitaxel (C), a novel taxane chemotherapy, has been found to prolong survival in patients who exhibit disease progression during or after D chemotherapy. Here, we review the first clinical studies in which castration-resistant prostate cancer patients received chemotherapy with D or C after progression during abiraterone acetate treatment.
Details
- Title: Subtitle
- Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate
- Creators
- Roberto Petrioli - University of SienaEdoardo Francini - Policlinico Umberto ILetizia Laera - University of SienaAnna Ida Fiaschi - University of SienaRoberto Ponchietti - University of SienaGiandomenico Roviello - University of Siena
- Resource Type
- Journal article
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.76(3), pp.439-445
- DOI
- 10.1007/s00280-015-2803-y
- PMID
- 26082421
- ISSN
- 0344-5704
- eISSN
- 1432-0843
- Publisher
- Springer Nature
- Number of pages
- 7
- Language
- English
- Date published
- 09/01/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221143502771
Metrics
1 Record Views